Answers are grounded in this paper and cite their sources.
Parkinson’s Disease (PD) is a common chronic progressive neurodegenerative disorder. Traditionally, it has been considered to be a disorder confined to dopaminergic neuronal injury in the substantia nigra of the central nervous system. However, increasing evidence from epidemiology, clinical imaging, and molecular biology suggests that the pathological process of PD may begin in the gut, with the gut–brain axis participating in disease initiation and progression. This review systematically summarizes the structural and physiological regulatory mechanisms of the gut–brain axis, focusing in particular on the aggregation of α-synuclein in the gut and its prion-like propagation, features of gut microbiota dysbiosis, leaky gut and systemic inflammatory cascades, and vagus nerve–related transmission mechanisms. Centering on prodromal PD, we discuss in depth early biomarkers based on this framework and propose a multi-dimensional combinatorial strategy integrating gut microbiota, barrier-related molecules and prodromal clinical phenotypes, to provide new perspectives for the prodromal prediction of PD.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: